136 results
Page 2 of 7
8-K
EX-99.1
nbjb7 gu9
16 Dec 22
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
8:17am
8-K
EX-99.1
r9u3d slu4k
16 Nov 22
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
7:01am
424B5
73st8061kk13lc4rn1
7 Nov 22
Prospectus supplement for primary offering
7:11am
8-K
EX-99.1
fv8 yid06a4a
14 Sep 22
Corporate Overview September 2022 At the Forefront of Therapies for Rare Diseases
7:00am
8-K
EX-99.1
cho3knegrp3a3vlc2z
10 Jan 22
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
7:00am
S-3ASR
g4gioybf
9 Nov 21
Automatic shelf registration
5:05pm
8-K
EX-99.3
7vzn 5ewjxr8
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am
8-K
EX-99.1
ksjan3cgbaph gvfg
2 Aug 21
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
7:00am
8-K
EX-99.1
ufialabmil77ne4k
8 Jun 21
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
7:00am
S-3ASR
tbmu69kdj2umesf
2 Feb 21
Automatic shelf registration
8:11am